Significance of plasma neuropeptide Y (NPY) in diagnosis and prognosis of neuroblastoma. 1991

Y Hayashi, and R Ohi, and M Sone, and K Takahashi, and T Mouri, and T Watanabe, and S Yaoita, and M Nakamura
Department of Pediatric Surgery, Tohoku University School of Medicine, Sendai, Japan.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D009478 Neuropeptide Y A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones. Neuropeptide Y-Like Immunoreactive Peptide,Neuropeptide Tyrosine,Neuropeptide Y Like Immunoreactive Peptide,Tyrosine, Neuropeptide
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005312 Fetal Blood Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery. Cord Blood,Umbilical Cord Blood,Blood, Cord,Blood, Fetal,Blood, Umbilical Cord,Bloods, Cord,Bloods, Fetal,Bloods, Umbilical Cord,Cord Blood, Umbilical,Cord Bloods,Cord Bloods, Umbilical,Fetal Bloods,Umbilical Cord Bloods
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

Y Hayashi, and R Ohi, and M Sone, and K Takahashi, and T Mouri, and T Watanabe, and S Yaoita, and M Nakamura
January 1991, Progress in clinical and biological research,
Y Hayashi, and R Ohi, and M Sone, and K Takahashi, and T Mouri, and T Watanabe, and S Yaoita, and M Nakamura
February 2007, Peptides,
Y Hayashi, and R Ohi, and M Sone, and K Takahashi, and T Mouri, and T Watanabe, and S Yaoita, and M Nakamura
September 1998, Regulatory peptides,
Y Hayashi, and R Ohi, and M Sone, and K Takahashi, and T Mouri, and T Watanabe, and S Yaoita, and M Nakamura
November 2008, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
Y Hayashi, and R Ohi, and M Sone, and K Takahashi, and T Mouri, and T Watanabe, and S Yaoita, and M Nakamura
January 2004, Pulmonary pharmacology & therapeutics,
Y Hayashi, and R Ohi, and M Sone, and K Takahashi, and T Mouri, and T Watanabe, and S Yaoita, and M Nakamura
January 1991, Fundamental & clinical pharmacology,
Y Hayashi, and R Ohi, and M Sone, and K Takahashi, and T Mouri, and T Watanabe, and S Yaoita, and M Nakamura
September 1992, Blood,
Y Hayashi, and R Ohi, and M Sone, and K Takahashi, and T Mouri, and T Watanabe, and S Yaoita, and M Nakamura
May 1998, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Y Hayashi, and R Ohi, and M Sone, and K Takahashi, and T Mouri, and T Watanabe, and S Yaoita, and M Nakamura
January 2007, Current topics in medicinal chemistry,
Y Hayashi, and R Ohi, and M Sone, and K Takahashi, and T Mouri, and T Watanabe, and S Yaoita, and M Nakamura
June 1990, Ma zui xue za zhi = Anaesthesiologica Sinica,
Copied contents to your clipboard!